Literature DB >> 9825730

Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.

V Pavillard1, P Formento, P Rostagno, J L Formento, J L Fischel, M Francoual, M C Etienne, G Milano.   

Abstract

We evaluated the combination SN38 (7-ethyl-10-hydroxycamptothecin) -5fluorouracil (5FU) +/- folinic acid (FA) on six human colon cancer cell lines expressing spontaneous sensitivity to both drugs. Tumoral parameters potentially related to drug sensitivity were investigated: topoisomerase I (topo I) cleavable complexes formed with SN38, thymidylate synthase (TS) activity, folylpolyglutamate synthetase activity and dihydropyrimidine dehydrogenase activity. Drugs (SN38 and/or 5FU +/- FA) were applied for 72 hr, either sequentially or together. The concentration ratio between SN38 and 5FU was 100. Cytotoxicity (MTT [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide] test), DNA flow cytometry and isobologram analysis (Chou and Talatay) were performed. Based on 5FU IC50 values and isobologram analyses, the most cytotoxic schedule was SN38 followed by 5FU - FA, with high synergistic effects. Flow cytometry indicated that SN38 induced a more or less marked S-G2 block in all cell lines. Sensitivity to SN38, 5FU +/- FA, or combinations were not linked to the potential above-cited tumoral parameters. Interestingly, an inverse correlation was demonstrated between TS activity and topo I cleavable complexes (r2 = 0.78, P = 0.019). These data emphasize the critical importance of the irinotecan-5FU schedule and strongly support this association for the treatment of potentially 5FU-sensitive tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9825730     DOI: 10.1016/s0006-2952(98)00205-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?

Authors:  Ramya Thota; Anirban Maitra; Jordan D Berlin
Journal:  Pancreas       Date:  2017-02       Impact factor: 3.327

2.  Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test.

Authors:  Takumi Ochiai; Kazuhiko Nishimura; Tomoo Watanabe; Masayuki Kitajima; Tadasuke Hashiguchi; Akinori Nakatani; Takashi Marusasa; Akira Muraki; Isao Nagaoka; Shunji Futagawa
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

Review 3.  Current Standards of Chemotherapy for Pancreatic Cancer.

Authors:  May Tun Saung; Lei Zheng
Journal:  Clin Ther       Date:  2017-09-19       Impact factor: 3.393

4.  The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.

Authors:  Matthias Ocker; Abdullah Alajati; Marion Ganslmayer; Steffen Zopf; Mike Lüders; Daniel Neureiter; Eckhart G Hahn; Detlef Schuppan; Christoph Herold
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-08       Impact factor: 4.553

5.  Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.

Authors:  Yasuhiro Inoue; Chikao Miki; Hideki Watanabe; Junichiro Hiro; Yuji Toiyama; Eiki Ojima; Hidenori Yanagi; Masato Kusunoki
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

6.  Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.

Authors:  Hong Jae Chon; Sun Young Rha; Hyung Soon Park; Sang Joon Shin; Hyo Song Kim; Jae Kyung Roh; Sung Hoon Noh; Hyun Cheol Chung; Hei-Cheul Jeung
Journal:  Cancer Chemother Pharmacol       Date:  2011-02-16       Impact factor: 3.333

7.  Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.

Authors:  J L Fischel; P Rostagno; P Formento; A Dubreuil; M C Etienne; G Milano
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

8.  A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.

Authors:  A Mercalli; V Sordi; R Formicola; M Dandrea; S Beghelli; A Scarpa; V Di Carlo; M Reni; L Piemonti
Journal:  Br J Cancer       Date:  2007-04-10       Impact factor: 7.640

9.  FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.

Authors:  Angélique Vienot; Hortense Chevalier; Clément Bolognini; Elisabeta Gherga; Elodie Klajer; Aurélia Meurisse; Marine Jary; Stefano Kim; Christelle d'Engremont; Thierry Nguyen; Fabien Calcagno; Hamadi Almotlak; Francine Fein; Meher Nasri; Syrine Abdeljaoued; Anthony Turpin; Christophe Borg; Dewi Vernerey
Journal:  World J Gastrointest Oncol       Date:  2020-03-15

Review 10.  The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis.

Authors:  Beilei Zhang; Fengyan Zhou; Jiaze Hong; Derry Minyao Ng; Tong Yang; Xinyu Zhou; Jieyin Jin; Feifei Zhou; Ping Chen; Yunbao Xu
Journal:  World J Surg Oncol       Date:  2021-06-21       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.